Revolutionizing Treatment: Breakthrough Approaches for BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer

Author:

Jaromin Maciej1ORCID,Konecki Tomasz1,Kutwin Piotr1

Affiliation:

1. 1st Department of Urology, Medical University of Lodz, 93-513 Lodz, Poland

Abstract

Bladder cancer is the 10th most popular cancer in the world, and non-muscle-invasive bladder cancer (NMIBC) is diagnosed in ~80% of all cases. Treatments for NMIBC include transurethral resection of the bladder tumor (TURBT) and intravesical instillations of Bacillus Calmette-Guérin (BCG). Treatment of BCG-unresponsive tumors is scarce and usually leads to Radical Cystectomy. In this paper, we review recent advancements in conservative treatment of BCG-unresponsive tumors. The main focus of the paper is FDA-approved medications: Pembrolizumab and Nadofaragene Firadenovec (Adstiladrin). Other, less researched therapeutic possibilities are also included, namely: N-803 immunotherapy, TAR-200 and TAR-210 intravesical delivery systems and combined Cabazitaxel, Gemcitabine and Cisplatin chemotherapy. Conservative treatment and delaying radical cystectomy would greatly benefit patients’ quality of life; it is undoubtedly the future of BCG-unresponsive NMIBC.

Publisher

MDPI AG

Reference71 articles.

1. Centers for Disease Control and Prevention (2020). Male Urologic Cancers, Centers for Disease Control and Prevention, US Department of Health and Human Services. USCS Data Brief, no 21.

2. Sex disparities in cancer incidence by period and age;Cook;Cancer Epidemiol. Biomark. Prev.,2009

3. Kaseb, H., and Aeddula, N.R. (2024, February 02). Bladder Cancer. [Updated 2022 October 24], StatPearls, Available online: https://www.ncbi.nlm.nih.gov/books/NBK536923/.

4. The accuracy of cystoscopy in predicting muscle invasion in newly diagnosed bladder cancer patients;Bruins;World J. Urol.,2023

5. Prediction of non-muscle invasive bladder cancer recurrence using machine learning of quantitative nuclear features;Tokuyama;Mod. Pathol.,2022

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3